Stock IVBI.Y INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Innovent Biologics, Inc. Share Price OTC Markets

Equities

IVBI.Y

US45783L1017

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 11:43:26 26/06/2024 pm IST 		5-day change 1st Jan Change
19.68 USD +0.92% Intraday chart for Innovent Biologics, Inc. -0.35% -5.79%
25/06 Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China DJ
25/06 Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions CI

Financials

Sales 2024 * 7.62B 1.05B 87.45B Sales 2025 * 9.97B 1.37B 114B Capitalization 59.17B 8.14B 679B
Net income 2024 * -842M -116M -9.66B Net income 2025 * 51M 7.02M 585M EV / Sales 2024 * 7.14 x
Net cash position 2024 * 4.79B 660M 55.04B Net cash position 2025 * 4.16B 573M 47.79B EV / Sales 2025 * 5.52 x
P/E ratio 2024 *
-69.4 x
P/E ratio 2025 *
775 x
Employees 4,872
Yield 2024 *
-
Yield 2025 *
0.01%
Free-Float 92.93%
More Fundamentals * Assessed data

Chart Innovent Biologics, Inc.

Dynamic Chart

Latest news about Innovent Biologics, Inc.

Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China DJ
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions CI
Innovent Biologics, Inc Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer CI
Innovent Biologics, Inc. Presents at 2024 ASCO Annual Meeting on Clinical Data of Anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer CI
Innovent Biologics, Inc. Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib (ROS1 Inhibitor) Publishes in JCO and Reports at 2024 ASCO Annual Meeting CI
Innovent Biologics, Inc. Presents Phase 1 Clinical Data of First-In-Class PD-1/IL-2a Bispecific Antibody Fusion Protein in Melanoma, Colorectal Cancer and Other Solid Tumors at 2024 ASCO Annual Meeting CI
Innovent Biologics, Inc. Announces Picankibart Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA CI
Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug MT
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311 CI
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer CI
Innovent Biologics, Inc. Announces Board and Committee Changes CI
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024 CI
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer CI
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer CI
Hutchmed endometrial cancer treatment application accepted for review AN
More news

Analyst Recommendations on Innovent Biologics, Inc.

Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy MT
Nomura Adjusts Innovent Biologics’ Price Target to HK$54.51 From HK$45.73, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.73 From SG$54.72, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$54.72 From HK$45.44, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.44 From HK$45.38, Keeps at Buy MT
More recommendations

Press releases Innovent Biologics, Inc.

Innovent Reports Oncology Pipeline Updates at Investor Meeting AQ
Innovent Announces Picankibart Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA AQ
Innovent Announces the New Drug Application of IBI311 has been accepted by the NMPA of China for Thyroid Eye Disease AQ
Innovent Biologics Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 and IBI343 AQ
Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints AQ
More press releases

News in other languages on Innovent Biologics, Inc.

La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las expectativas -- Market Talk
Les valeurs à suivre aujourd'hui à la Bourse de Paris Vendredi 5 août 2022
Le CAC 40 attendu en légère hausse avant l'emploi américain
Sanofi : collaboration avec Innovent Biologics en Chine
Sanofi et Innovent Biologics collaborent sur des anticancéreux en Chine
More news

Quotes and Performance

1 day+0.92%
1 week-0.35%
Current month+1.03%
1 month+1.03%
3 months+5.47%
6 months-5.79%
Current year-5.79%
More quotes

Highs and lows

1 week
19.50
Extreme 19.5
19.68
1 month
19.50
Extreme 19.5
19.75
Current year
18.66
Extreme 18.66
24.14
1 year
18.66
Extreme 18.66
24.14
3 years
18.66
Extreme 18.66
24.14
5 years
18.66
Extreme 18.66
24.14
10 years
18.66
Extreme 18.66
24.14
More quotes

Managers and Directors - Innovent Biologics, Inc.

Managers TitleAgeSince
De Chao Yu CEO
 Chief Executive Officer 61 28/11/28
Fei You DFI
 Director of Finance/CFO 45 05/02
Yong-Jun Liu PSD
 President - 15/20/15
Members of the board TitleAgeSince
Gary Zieziula BRD
 Director/Board Member 69 31/22/31
Charles Cooney BRD
 Director/Board Member 80 18/15/18
De Chao Yu CEO
 Chief Executive Officer 61 28/11/28
More insiders

Quotes

Date Price Change Volume
26/24/26 19.68 +0.92% 200
25/24/25 19.5 -1.27% 210

Delayed Quote OTC Markets, June 26, 2024 at 11:43 pm IST

More quotes

Company Profile

Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Sector
Pharmaceuticals
Calendar
21/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Innovent Biologics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
36.35 CNY
Average target price
51.68 CNY
Spread / Average Target
+42.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+3.15% 94.74B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.68% 37.28B
BIOGEN INC. Stock Biogen Inc.
-11.61% 32.68B
UCB Stock UCB
+74.21% 27.72B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.40% 16.19B
INCYTE CORPORATION Stock Incyte Corporation
-2.29% 13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.21% 11.58B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+188.83% 10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-53.94% 9.54B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. IVBI.Y Stock